Author(s)

Huiling Chen, Hongxia Shi, Zhenglu Feng

Corresponding Author

Huiling Chen

ABSTRACT

Objective: To observe the effect of Lactobacillus vaginal capsule combined with recombinant human interferon α-2b gel in the treatment of patients with high-risk human papilloma virus (HPV) infection. Method: 90 patients with confirmed HPV infection who received treatment in our hospital from June 2020 to June 2022 were selected as the study subjects, and patients who received routine treatment in our hospital were selected as controls. The patients were divided into experimental group (n = 45) and control group (n = 45). The experimental group was treated with Lactobacillus vaginal capsule combined with recombinant human interferon α-2b gel, and the control group was treated with recombinant human interferon α-2b gel. The clinical efficacy of the two groups was compared to observe the changes of inflammatory indexes before and after treatment. Results: The total effective rate of the experimental group was 100%. The difference was mainly reflected in that the effective rate was 95.55% (43 / 45), which was higher than 8.88% (4 / 45) of the control group, and the difference was statistically significant (P < 0.05). The changes of inflammatory indexes after treatment in the two groups were observed, and it was found that TNF- α、 IL-6 and IL-10 in the experimental group were significantly lower than those in the control group (P < 0.05). No obvious adverse reactions were observed in the two groups during the treatment period. Conclusion: Lactobacillus vaginal capsule combined with recombinant human interferon α-2b gel has a good therapeutic effect on HPV infected patients, and can significantly reduce the level of inflammatory indicators, which is better than recombinant human interferon alone α-2b gel treatment.

KEYWORDS

Human papilloma virus, Recombinant human interferon α-2b, Lactobacillus vaginal capsule, Inflammatory index, HPV